CVS Health (NYSE:CVS) is a prominent player in the healthcare sector, offering a wide range of services including pharmacy benefits management, retail pharmacy, and healthcare services. As a major competitor in the industry, CVS faces competition from companies like Walgreens and Rite Aid. On February 10, 2026, CVS is set to release its quarterly earnings, with Wall Street estimating earnings per share (EPS) of $0.99 and revenue of approximately $103.57 billion.
In the past four quarters, CVS has consistently exceeded earnings estimates, showcasing its strong financial performance. However, despite the potential for another earnings beat, there is uncertainty about a post-earnings rally. This uncertainty stems from proposed changes in Medicare Advantage payment rates, which have already led to a significant drop in CVS shares by double-digit percentages.
For the fourth quarter of 2025, analysts expect CVS to report non-GAAP earnings of $0.99 per share, a decline from the $1.19 per share reported in the same quarter of 2024. This decline may be influenced by the Medicare news, which could impact investor sentiment and the stock's performance following the earnings announcement. The company's P/E ratio of 212 suggests that investors are willing to pay a high price for CVS's earnings, reflecting high expectations.
CVS's financial metrics provide further insight into its valuation. The price-to-sales ratio of 0.25 indicates that the market values CVS at 25 cents for every dollar of sales. Additionally, the enterprise value to sales ratio of 0.44 reflects the company's valuation in relation to its sales. The enterprise value to operating cash flow ratio of 18.89 highlights how the market values CVS's cash-generating ability.
The company's debt-to-equity ratio of 1.12 shows a moderate use of debt in its capital structure. However, the current ratio of 0.83 suggests potential liquidity concerns, as CVS has less than one dollar in current assets for every dollar of current liabilities. These financial metrics, along with the earnings yield of 0.47%, provide a comprehensive view of CVS's financial health and market valuation.
